Hepatitis C virus-human immunodeficiency virus coinfection

Research output: Contribution to journalArticle

Abstract

As a result of shared modes of transmission, chronic hepatitis C infection is common in HIV-infected patients, particularly among those who have used injection drugs as well as men who have sex with men (MSMs). In the era of effective antiretroviral therapy, HCV infection has emerged as a major cause of morbidity and mortality worldwide. Over the last decade, treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of HCV treatment in this population has been disappointing. Challenges to the use of HCV NS3/4A protease inhibitors, telaprevir and boceprevir, patients with HIV/HCV coinfection include the potential for interactions between different drugs, addition of drug toxicities, and the need for therapy with PEG-IFN. Despite these challenges, limited data indicate that telaprevir and boceprevir given in combination with PEG-IFN/RBV increase the rate of viral suppression in coinfected patients with manageable toxicity and drug-drug interaction profile. Accordingly, these agents may be recommended for HCV treatment in carefully selected HIV-infected persons.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalLiver International
Volume32
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 2012

Fingerprint

Coinfection
Hepacivirus
HIV
Ribavirin
Drug-Related Side Effects and Adverse Reactions
Chronic Hepatitis C
Therapeutics
Infection
Protease Inhibitors
Drug Interactions
Pharmaceutical Preparations
Liver Diseases
Morbidity
Injections
Mortality
Population
telaprevir
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide

Keywords

  • Boceprevir
  • HCV
  • HIV
  • Peginterferon
  • Ribavirin
  • Telaprevir

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis C virus-human immunodeficiency virus coinfection. / Sulkowski, Mark.

In: Liver International, Vol. 32, No. SUPPL. 1, 02.2012, p. 129-134.

Research output: Contribution to journalArticle

@article{df2d0005a9424e9e8dcb082298b3364a,
title = "Hepatitis C virus-human immunodeficiency virus coinfection",
abstract = "As a result of shared modes of transmission, chronic hepatitis C infection is common in HIV-infected patients, particularly among those who have used injection drugs as well as men who have sex with men (MSMs). In the era of effective antiretroviral therapy, HCV infection has emerged as a major cause of morbidity and mortality worldwide. Over the last decade, treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of HCV treatment in this population has been disappointing. Challenges to the use of HCV NS3/4A protease inhibitors, telaprevir and boceprevir, patients with HIV/HCV coinfection include the potential for interactions between different drugs, addition of drug toxicities, and the need for therapy with PEG-IFN. Despite these challenges, limited data indicate that telaprevir and boceprevir given in combination with PEG-IFN/RBV increase the rate of viral suppression in coinfected patients with manageable toxicity and drug-drug interaction profile. Accordingly, these agents may be recommended for HCV treatment in carefully selected HIV-infected persons.",
keywords = "Boceprevir, HCV, HIV, Peginterferon, Ribavirin, Telaprevir",
author = "Mark Sulkowski",
year = "2012",
month = "2",
doi = "10.1111/j.1478-3231.2011.02719.x",
language = "English (US)",
volume = "32",
pages = "129--134",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Hepatitis C virus-human immunodeficiency virus coinfection

AU - Sulkowski, Mark

PY - 2012/2

Y1 - 2012/2

N2 - As a result of shared modes of transmission, chronic hepatitis C infection is common in HIV-infected patients, particularly among those who have used injection drugs as well as men who have sex with men (MSMs). In the era of effective antiretroviral therapy, HCV infection has emerged as a major cause of morbidity and mortality worldwide. Over the last decade, treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of HCV treatment in this population has been disappointing. Challenges to the use of HCV NS3/4A protease inhibitors, telaprevir and boceprevir, patients with HIV/HCV coinfection include the potential for interactions between different drugs, addition of drug toxicities, and the need for therapy with PEG-IFN. Despite these challenges, limited data indicate that telaprevir and boceprevir given in combination with PEG-IFN/RBV increase the rate of viral suppression in coinfected patients with manageable toxicity and drug-drug interaction profile. Accordingly, these agents may be recommended for HCV treatment in carefully selected HIV-infected persons.

AB - As a result of shared modes of transmission, chronic hepatitis C infection is common in HIV-infected patients, particularly among those who have used injection drugs as well as men who have sex with men (MSMs). In the era of effective antiretroviral therapy, HCV infection has emerged as a major cause of morbidity and mortality worldwide. Over the last decade, treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of HCV treatment in this population has been disappointing. Challenges to the use of HCV NS3/4A protease inhibitors, telaprevir and boceprevir, patients with HIV/HCV coinfection include the potential for interactions between different drugs, addition of drug toxicities, and the need for therapy with PEG-IFN. Despite these challenges, limited data indicate that telaprevir and boceprevir given in combination with PEG-IFN/RBV increase the rate of viral suppression in coinfected patients with manageable toxicity and drug-drug interaction profile. Accordingly, these agents may be recommended for HCV treatment in carefully selected HIV-infected persons.

KW - Boceprevir

KW - HCV

KW - HIV

KW - Peginterferon

KW - Ribavirin

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84855232974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855232974&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2011.02719.x

DO - 10.1111/j.1478-3231.2011.02719.x

M3 - Article

C2 - 22212583

AN - SCOPUS:84855232974

VL - 32

SP - 129

EP - 134

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 1

ER -